News|Articles|October 3, 2019

CURE New Issue Alert: Immunotherapy Special Issue

Author(s)Katie Kosko, Brielle Benyon

Key Takeaways

Immunotherapy's evolution over 100 years has significantly impacted cancer treatment, revolutionizing patient care and research in oncology.
FDA approval of the first immunotherapy for metastatic triple-negative breast cancer offers new hope, allowing patients to move away from traditional chemotherapy.
CAR-T cell therapy presents promising outcomes but carries significant risks, as illustrated by a non-Hodgkin lymphoma survivor's personal journey and insights.

Here’s a look at what’s inside our 2019 Immunotherapy special issue.

Here’s a look at what’s inside our 2019 Immunotherapy special issue:

Immunotherapy has been a game-changer for patients with cancer and researchers. But how did this type of treatment come to life? This issue takes you back more than 100 years to see the evolution of immuno-oncology.

Next, the first immunotherapy for patients with metastatic triple-negative breast cancer is now approved by the FDA. Read the stories of two women who feel a renewed sense of hope and are happy to kick chemotherapy to the curb.

And, CAR-T cell therapy is the latest type of immunotherapy to offer great rewards — but with great risks. Walk in the shoes of a non-Hodgkin lymphoma survivor as he shares his firsthand experience and what he wished he had known before treatment.

To read these stories and more, check out the full issue online.

Or, ensure you don’t miss a story when you subscribe to new issue alerts.

And, as always, thanks for reading.